NCT05988970Completed
Impact of Circadian Rhythm on the Spread of Circulating Tumor Cells in Lung Cancer Patients
Source: ClinicalTrials.gov · Last updated 27 Jan 2026
Brief summary (registry, in English)
This is a prospective pilot study designed to demonstrate the impact of circadian rhythm on the spread of Circulating Tumor Cells (CTCs) in patients with Non- Small Cell Lung Cancer - NSCLC. 27 patients will be included in the study and will be followed for 12 months. For each included patient, blood samples will be collected before the anticancer treatment initiation.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 27 (actual)
- First submitted
- 3 Aug 2023
- Start date
- 29 Jan 2024
- Primary completion date
- 21 Jan 2026
- Lead sponsor
- Institut Claudius Regaud
- Diseases
- Lung cancer
- NCT number
- NCT05988970
What you commit to
- Study type: Interventional
- Participants enrolled: 27
- From 29 Jan 2024 to the primary completion date, 21 Jan 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient previously treated for NSCLC
Other illness
- Small-cell cancer or cancer with a majority small-cell contingent
- Patient with active pathology such as sepsis or uncontrolled inflammatory syndrome
- Any psychological, family, geographical or sociological condition that makes it impossible to comply with the medical follow-up and/or procedures stipulated in the study protocol.
Other
- Outpatient
- Any pathology contraindicating the sample collection procedures required by the study.
- Pregnant or breast-feeding women.
- Patients deprived of their liberty or under legal protection (guardianship, legal protection).
Who the study is looking for
- Patient with histologically confirmed advanced NSCLC (inoperable stage 3 or 4)
- Patient aged ≥ 18 years
- Life expectancy \> 3 months
- Patient naïve to treatment for NSCLC
- Patient hospitalized at least one night for initiation of specific treatment (chemotherapy, radiotherapy, surgery, other...)
- Patient with no other active cancer. Cancer history accepted if more than 3 years old and considered cured.
- Patient affiliated to a Social Security scheme in France.
- Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedure.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Larrey Coordinator of this site? Confirm its status | Toulouse | France | Unknown status |
| Institut Universitaire du Cancer de Toulouse - Oncopole Coordinator of this site? Confirm its status | Toulouse | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.